Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for behavioral variant frontotemporal dementia
2018-000143-12Phase 2Completed
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in frontotemporal dementia (FTD) (2 arms), sponsored by Alma Mater Studiorum – Università di Bologna. Primary endpoint: Improvement in social cognition performance. Started Jun 2023; status: completed.
02
Drugs
oxytocin
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on 2018-000143-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000143-12.